XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 6 - Goodwill and Intangible Assets, Net

9 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Text Block]

Note 6. Goodwill and Intangible Assets, Net

Finite-lived intangible assets consisted of the following:

	*December 31, 2024*							*March 31, 2024*
	*Gross Carrying Amount*		*Accumulated Amortization*			*Net Carrying Amount*		*Gross Carrying Amount*		*Accumulated Amortization*			*Net Carrying Amount*
Customer relationships	$	186,272	$	(112,475	)	$	73,797	$	189,911	$	(104,528	)	$	85,383
Other intangibles		60,356		(35,972	)		24,384		61,161		(32,792	)		28,369
Total finite-lived intangible assets	$	246,628	$	(148,447	)	$	98,181	$	251,072	$	(137,320	)	$	113,752

Amortization expense for finite-lived intangible assets was as follows:

	*Three Months Ended December 31,*				*Nine Months Ended December 31,*
	*2024*		*2023*		*2024*		*2023*
Amortization in cost of revenues	$	660	$	1,883	$	1,979	$	5,367
Amortization in general and administrative		3,731		6,092		11,023		17,013
Total amortization expense	$	4,391	$	7,975	$	13,002	$	22,380

The decrease in amortization expense is attributable to impairment losses recorded during the fourth quarter of fiscal year 2024 related to intangible assets within our Clinical Genomics division.

For the following fiscal years ending March 31, future amortization expense is estimated as follows, based on foreign currency exchange rates as of December 31, 2024:

Fiscal Year	*Amortization Expense*
Fiscal Year	*Amortization Expense*
Remainder of 2025	$	4,278
2026		16,566
2027		15,921
2028		15,349
2029		14,815

The change in the carrying amount of goodwill was as follows:

	*Sterilization and Disinfection Control*			*Clinical Genomics*			*Biopharmaceutical Development*			*Calibration Solutions*			*Total*
March 31, 2024	$	79,430		$	16,940		$	46,515		$	37,211			180,096
Effect of foreign currency translation		(1,994	)		(71	)		(849	)		(30	)		(2,944	)
December 31, 2024	$	77,436		$	16,869		$	45,666		$	37,181		$	177,152